A comprehensive investigation has uncovered a notable correlation between the utilization of estrogen-only hormone therapy in post-menopausal women and a diminished presence of key pathological indicators of Alzheimer’s disease within the brain, alongside a reduced likelihood of clinical dementia diagnoses. The findings, published on August 12, 2026, in the esteemed medical journal Neurology, offer a nuanced perspective on the long-term impact of specific hormone interventions on cognitive aging. This extensive research, involving over 21,000 participants, delved into the intricate relationship between past hormone therapy use and the neuropathological hallmarks of Alzheimer’s, as well as clinical assessments of cognitive function.
It is crucial to underscore that the study’s authors emphasize the observational nature of these results, asserting that the data demonstrate an association rather than proving a causal link or a preventative effect of hormone therapy on dementia. Dr. Jennifer Bruno, a lead researcher from Stanford Medicine, highlighted the critical distinction between the historical context of hormone therapy use examined in the study and contemporary medical practices. "While these findings significantly contribute to our understanding of how hormone therapy interacts with various markers of dementia, further extensive research is imperative before we can formulate definitive recommendations for women regarding the use of these therapies in the context of their brain health," Dr. Bruno stated. She further elaborated, "The methodology of this study involved retrospectively examining women who engaged in hormone therapy decades ago, with the timing and specific regimens differing considerably from the standard protocols prevalent today. Consequently, while the insights are valuable, their direct applicability to current therapeutic standards may be limited."
The research team meticulously analyzed data from two substantial cohorts, aggregating information from 21,462 women who underwent clinical evaluations during their lifetimes. Within these cohorts, a subset of participants, numbering 728, received advanced neuroimaging scans or biomarker analyses while alive. In a parallel examination, the brains of 2,959 participants were subjected to post-mortem autopsies. These autopsies, conducted on average when participants were 82 years old, allowed researchers to meticulously search for the pathological signatures characteristic of Alzheimer’s disease. The follow-up period for participants in both data sets spanned approximately three to five years, commencing at an average age of 71.
Across the entirety of the study population, 1,953 women reported having used hormone therapy, while a significantly larger group of 19,509 women had not. The average age at which women in the hormone therapy group initiated treatment was after their 70th birthday. A critical parameter of the analysis was its exclusive focus on estrogen-only hormone therapy. This specific focus stemmed from prior research suggesting that combined hormone therapy, involving both estrogen and progestin, might potentially elevate the risk of dementia. In current clinical practice, estrogen-only therapy is typically reserved for individuals who have undergone a hysterectomy, primarily to mitigate the risk of endometrial cancer.
The post-mortem examination of participants’ brains revealed a striking disparity: those who had previously utilized hormone therapy exhibited a notably lower prevalence of Alzheimer’s disease pathology. Researchers meticulously evaluated three cardinal neuropathological features consistently associated with Alzheimer’s disease: amyloid-beta plaques, neurofibrillary tangles composed of tau protein, and neuritic plaques, which are characterized by amyloid plaques encircled by degenerated nerve cells. These findings were integrated into a composite score designed to quantify the overall burden of Alzheimer’s-related pathology within the brain.
The autopsy results indicated that 18% of women who had undergone hormone therapy showed no discernible signs of Alzheimer’s disease. This contrasts sharply with the 10% observed in the group of women who had not used hormone therapy. Conversely, at the more severe end of the spectrum, 40% of hormone therapy users displayed all three hallmark signs of Alzheimer’s pathology, compared to a higher proportion of 51% among women who had not used the therapy. Even after controlling for a range of confounding variables, including age, educational attainment, genetic predispositions, race, and the presence of hypertension, the use of hormone therapy remained associated with a 35% reduction in the odds of exhibiting Alzheimer’s pathology at autopsy.
Further substantiating these findings, a separate analysis centered on biomarker data collected from participants while they were still alive. Women who had used hormone therapy exhibited amyloid biomarker levels in both their blood and cerebrospinal fluid that were indicative of reduced amyloid accumulation in the brain, when compared to their counterparts who had not used hormone therapy. Elevated levels of amyloid-beta protein in peripheral fluids can, in some contexts, suggest a lesser degree of protein deposition within the brain as plaques.
The impact of hormone therapy extended beyond neuropathological markers. The analysis of biomarker data also revealed that hormone therapy use was associated with a 39% lower probability of receiving a clinical diagnosis of dementia. Furthermore, women who had utilized the therapy were less prone to reporting memory impairments or experiencing declines in their capacity to perform daily functional activities.
However, the researchers explicitly acknowledged a significant limitation inherent in the study’s design: the pattern of hormone therapy use among the participants differed substantially from current clinical standards. Dr. Bruno pointed out that the average age at which participants in the study began hormone therapy was around 70 years old. In contrast, current medical guidelines generally advocate for initiating hormone therapy in the late 40s to early 50s, with treatment typically discontinued before the age of 60. This temporal discrepancy is crucial for interpreting the findings, as the biological effects and optimal timing of hormone interventions may have evolved.
Despite these acknowledged limitations, Dr. Bruno concluded that "the findings provide compelling evidence of an association between the use of estrogen-only hormone therapy during later life and more favorable outcomes in terms of dementia prevalence and overall brain health." The research was generously supported by funding from the National Institute on Aging, underscoring the national importance placed on understanding and mitigating the impact of neurodegenerative diseases. This study represents a significant step in unraveling the complex interplay between hormonal changes and brain health in aging women, paving the way for future research to refine our understanding and potentially inform therapeutic strategies.
About the Author
